GMP-compatible fluoropolymer closed culture systems for manufacturing and controlled aggregation of stem cell-derived pancreatic progenitors for diabetes cell therapy

Authors

• Praveen Pedabaliyarasimhuni, McGill University, CanadaFollow
• Balaji Ramachandran, Department of Chemical Engineering, McGill University, Montreal, QC, Canada
• Will Yoon, Department of Chemical Engineering, McGill University, Montreal, QC, Canada
• Demetry Prezelj, Department of Chemical Engineering, McGill University, Montreal, QC, Canada
• Lyne Khair, Saint-Gobain Life Sciences, Bioprocess Solutions, Northborough, MA, USA
• Nicolas Drolet, Saint-Gobain Life Sciences, Bioprocess Solutions, Northborough, MA, USA
• Katie Campbell, Saint-Gobain Life Sciences, Bioprocess Solutions, Northborough, MA, USA
• Corinne A Hoesli, Department of Chemical Engineering, McGill University, Montreal, QC, Canada

Conference Dates

February 1 – 5, 2026

Abstract

Please click Additional Files below to see the full abstract

Recommended Citation

Praveen Pedabaliyarasimhuni, Balaji Ramachandran, Will Yoon, Demetry Prezelj, Lyne Khair, Nicolas Drolet, Katie Campbell, and Corinne A Hoesli, "GMP-compatible fluoropolymer closed culture systems for manufacturing and controlled aggregation of stem cell-derived pancreatic progenitors for diabetes cell therapy" in "Advancing Manufacture of Cell and Gene Therapies IX [2026]", John Moscariello, Neuvogen, USA Corinne Hoesli, McGill University, Canada Bruno Marques, Century Therapeutics, USA Eds, ECI Symposium Series, (2026). https://dc.engconfintl.org/cell_gene_therapies_ix/93